신경학적 바이오마커 시장 : 바이오마커 유형, 기술 플랫폼, 검체 근원, 용도, 최종 사용자별 예측(2026-2032년)

The Neurological Biomarkers Market is projected to grow by USD 21.74 billion at a CAGR of 13.90% by 2032.

Neurological biomarkers are measurable indicators of disease biology, treatment response, or risk across conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, traumatic brain injury, stroke, and rare neurodegenerative disorders. The field is moving beyond specialist neuroimaging and cerebrospinal fluid testing toward scalable blood-based biomarkers, digital biomarkers, neurophysiology, genomics, proteomics, metabolomics, and AI-enabled image analytics.

Demand is reinforced by the global burden of neurological disease. The World Health Organization reported in 2024 that neurological conditions affect more than 3 billion people worldwide, while dementia affects more than 55 million people and epilepsy affects around 50 million. These epidemiological pressures are elevating neurological biomarkers from research tools to essential infrastructure for earlier diagnosis, patient stratification, clinical trial enrichment, and monitoring of disease progression.

The opportunity is strongest where validated biomarkers reduce diagnostic uncertainty, shorten clinical development timelines, and support precision neurology. Blood-based Alzheimer's biomarkers, neurofilament light chain for neuroaxonal injury, amyloid and tau PET, advanced MRI, EEG-based indicators, and digital motor and cognitive measures are becoming central to clinical and commercial strategies.

Transformative Shifts in the Neurological Biomarkers Landscape

The neurological biomarkers landscape is being reshaped by three structural shifts: the move from late-stage diagnosis to earlier risk detection, the shift from single-modality testing to multi-omics and multimodal data integration, and the transition from research-grade assays to clinically deployable diagnostics. These shifts are driven by the need to detect disease biology before irreversible neurodegeneration and to match patients with targeted therapies.

Alzheimer's disease is a leading example. Disease-modifying therapies that require confirmation of amyloid pathology have increased the need for PET, CSF, and emerging plasma biomarkers, while also strengthening demand for objective monitoring of safety and treatment response. In multiple sclerosis and traumatic brain injury, neurofilament light chain is gaining traction as a marker of neuronal injury, while digital biomarkers are expanding continuous assessment beyond episodic clinic visits.

Commercial differentiation is increasingly tied to analytical validity, clinical validity, clinical utility, regulatory readiness, payer evidence, and interoperability with electronic health records and decentralized trial platforms. Organizations that combine biomarker performance with workflow integration are better positioned than those offering isolated assays.

Cumulative Impact of Artificial Intelligence on Neurological Biomarkers

Artificial intelligence is accelerating neurological biomarker discovery and deployment by improving pattern recognition in imaging, electrophysiology, speech, gait, cognition, and wearable sensor data. AI models can help identify subtle changes in MRI, PET, retinal imaging, EEG, and digital behavior streams that may be difficult to detect through conventional clinical review.

The regulatory environment is also maturing. The U.S. FDA's public inventory of AI/ML-enabled medical devices had surpassed 950 authorized devices by 2024, with radiology representing the largest category, indicating broad acceptance of AI-assisted interpretation when supported by evidence. In neurology, AI is most valuable when it enhances reproducibility, reduces reader variability, improves triage, and supports longitudinal measurement.

The cumulative impact is a shift from biomarker measurement to biomarker intelligence. However, leaders must manage model bias, data provenance, cybersecurity, explainability, and post-market performance monitoring. AI-enabled neurological biomarkers will gain trust fastest when trained on diverse datasets and validated prospectively across populations, devices, and care settings.

Key Regional Insights for Neurological Biomarkers

North America remains a leading region for neurological biomarker innovation due to strong academic medical centers, active clinical trial infrastructure, established regulatory pathways, and adoption of advanced neuroimaging and molecular diagnostics. The United States anchors commercialization through FDA engagement, payer evidence development, and specialty neurology networks, while Canada contributes through neuroscience research programs, public health data assets, and population-level research infrastructure.

Europe is characterized by coordinated research, biobanks, and regulatory rigor under frameworks such as the In Vitro Diagnostic Regulation and General Data Protection Regulation. The European Union's emphasis on health data governance supports high-quality evidence generation, while the United Kingdom, Germany, France, Italy, and Spain remain important centers for clinical research, diagnostics adoption, dementia programs, and neurodegenerative disease studies.

Asia-Pacific is expanding as China, Japan, India, South Korea, and Australia invest in neuroscience, genomics, AI health technologies, and aging-related care. Latin America, led by Brazil and Mexico, shows rising demand for neurological diagnostics but continues to face access, reimbursement, and specialist availability constraints. The Middle East, especially GCC healthcare hubs, is building tertiary neurology, precision medicine, and digital health capacity, while Africa presents long-term potential through improved diagnostics, research partnerships, workforce development, and scalable point-of-care approaches.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, demand for neurological biomarkers is shaped by population growth, expanding private healthcare, and increasing attention to dementia, stroke, epilepsy, and neurodevelopmental disorders, although access to PET imaging, advanced MRI, and specialized laboratories remains uneven across member states. The GCC is investing in tertiary care, precision medicine, genomic initiatives, and digital health infrastructure, creating a favorable environment for high-value neurological diagnostics in urban health systems and specialist centers.

The European Union offers one of the most structured environments for biomarker evidence generation, supported by multicountry research programs, biobanks, harmonized regulatory expectations, and strong data protection requirements. BRICS economies combine high disease burden with expanding diagnostic capacity, making affordability, local clinical validation, workforce development, and scalable blood-based assays critical to broader adoption.

G7 markets represent the strongest concentration of reimbursement systems, pharmaceutical R&D, advanced imaging infrastructure, and specialty neurology capacity, supporting faster translation of validated neurological biomarkers into clinical and trial workflows. NATO countries overlap significantly with high-income markets where traumatic brain injury research, veteran brain health, secure health data systems, and resilient medical infrastructure can influence biomarker deployment.

Key Country Insights for Neurological Biomarker Adoption

The United States leads in commercialization, FDA interactions, clinical trial activity, advanced imaging, laboratory-developed testing, and payer-driven evidence requirements, while Canada provides strong neuroscience research and public health data capabilities. Mexico and Brazil are important Latin American markets where growing specialty care, academic research, and clinical trial activity coexist with affordability, reimbursement, and access challenges.

In Europe, the United Kingdom, Germany, and France are central to biomarker research, diagnostics adoption, dementia initiatives, and pharmaceutical partnerships. Italy and Spain contribute through strong neurology networks, aging populations, and clinical trial participation, while Russia has scientific and clinical capacity but faces geopolitical, regulatory, and market access constraints.

In Asia-Pacific, China is scaling biotechnology, AI, genomics, and diagnostics infrastructure; India offers a large patient population and expanding laboratory networks; Japan has a high aging burden and advanced medical technology adoption; Australia supports high-quality clinical research and neurodegenerative disease programs; and South Korea is a strong digital health, imaging, and medtech innovation hub.

Actionable Recommendations for Neurological Biomarker Leaders

Industry leaders should prioritize biomarkers with clear clinical utility, not only analytical performance. The strongest opportunities are in tests that guide therapy selection, confirm disease pathology, identify progression risk, reduce clinical trial screen failures, or monitor treatment response in real-world neurology settings.

Organizations should build evidence packages that include diverse cohorts, longitudinal outcomes, health economic value, and real-world performance. Partnerships with academic centers, biobanks, clinical trial networks, imaging providers, pharmaceutical sponsors, and digital health platforms can accelerate validation, regulatory readiness, and adoption.

Executives should also invest in regulatory strategy, data governance, interoperability, cybersecurity, and payer engagement early. Scalable blood-based assays, AI-enabled imaging workflows, and digital biomarkers should be designed for integration into neurology clinics, memory centers, emergency care, decentralized trials, and remote monitoring programs.

Research Methodology

This executive summary is developed using a secondary research framework focused on verified public sources, peer-reviewed scientific literature, regulatory information, disease burden data, and healthcare infrastructure indicators. Key reference categories include WHO neurological disease statistics, FDA device and diagnostic information, EMA and EU regulatory frameworks, national health agencies, clinical trial registries, and published clinical consensus statements.

The analysis evaluates biomarker modalities including blood, CSF, neuroimaging, electrophysiology, digital biomarkers, genetics, proteomics, and metabolomics. Interpretation emphasizes clinical adoption, regulatory readiness, reimbursement potential, competitive differentiation, regional healthcare capacity, and evidence requirements for precision neurology.

Insights are synthesized to support executive decision-making without presenting unverified market sizing, market share, or forecasts. Where numeric data are included, they reflect publicly reported disease burden or regulatory indicators from recognized sources.

Conclusion

Neurological biomarkers are becoming foundational to precision neurology as healthcare systems seek earlier diagnosis, better patient stratification, and objective monitoring of complex brain disorders. The convergence of blood-based testing, advanced imaging, digital measures, neurophysiology, multi-omics, and artificial intelligence is expanding use cases from research and clinical trials into routine care pathways.

The next phase of adoption will depend on validation, equity, reimbursement, regulatory confidence, and trust. Organizations that combine scientific rigor with scalable deployment, strong data governance, workflow integration, and payer-relevant evidence will be best positioned to lead in the neurological biomarkers landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neurological Biomarkers Market, by Biomarker Type

• 7.1. Protein Biomarkers
  • 7.1.1. Tau Proteins
  • 7.1.2. Amyloid-Beta
  • 7.1.3. Neurofilament Light Chain
  • 7.1.4. Alpha-Synuclein
• 7.2. Genetic Biomarkers
  • 7.2.1. APOE Genotype
  • 7.2.2. Mutations
  • 7.2.3. Copy Number Variations
  • 7.2.4. Microsatellite Markers
• 7.3. Proteomic Biomarkers
• 7.4. Metabolic Biomarkers
• 7.5. Metabolomic Biomarkers
• 7.6. Oxidative Stress Biomarkers

8. Neurological Biomarkers Market, by Technology Platform

• 8.1. Enzyme-Linked Immunosorbent Assay
• 8.2. Imaging Techniques
  • 8.2.1. Computed Tomography
  • 8.2.2. Functional Near-Infrared Spectroscopy
  • 8.2.3. Magnetic Resonance Imaging
  • 8.2.4. Positron Emission Tomography
• 8.3. Mass Spectrometry
• 8.4. Next-Generation Sequencing
  • 8.4.1. RNA Sequencing
  • 8.4.2. Targeted Resequencing
  • 8.4.3. Whole Genome Sequencing
• 8.5. Polymerase Chain Reaction

9. Neurological Biomarkers Market, by Specimen Source

• 9.1. Cerebrospinal Fluid
• 9.2. Blood-Based
  • 9.2.1. Serum
  • 9.2.2. Plasma
  • 9.2.3. Whole Blood
  • 9.2.4. Dried Blood Spots
• 9.3. Urine
• 9.4. Saliva

10. Neurological Biomarkers Market, by Application

• 10.1. Diagnostics
• 10.2. Drug Development
• 10.3. Monitoring
• 10.4. Prognostics
• 10.5. Research

11. Neurological Biomarkers Market, by End User

• 11.1. Contract Research Organizations
• 11.2. Diagnostic Laboratories
• 11.3. Hospitals & Clinics
• 11.4. Pharmaceutical & Biotechnology Companies
• 11.5. Research Institutes

12. Neurological Biomarkers Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Neurological Biomarkers Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Neurological Biomarkers Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Acumen Pharmaceuticals Inc.
• 16.3. ADx NeuroSciences NV
• 16.4. Agilent Technologies, Inc.
• 16.5. Alector Inc.
• 16.6. Altoida Inc.
• 16.7. Banyan Biomarkers, Inc.
• 16.8. Becton, Dickinson and Company
• 16.9. Bio-Rad Laboratories, Inc.
• 16.10. Bio-Techne Corporation
• 16.11. Biogen Inc.
• 16.12. bioMerieux SA
• 16.13. Bruker Corporation
• 16.14. C2N Diagnostics, LLC
• 16.15. Charles River Laboratories International, Inc.
• 16.16. CND Life Sciences
• 16.17. Danaher Corporation
• 16.18. Eli Lilly and Company
• 16.19. Euroimmun AG
• 16.20. F. Hoffmann-La Roche AG
• 16.21. GE HealthCare Technologies Inc.
• 16.22. Illumina, Inc.
• 16.23. Invicro LLC
• 16.24. Johnson & Johnson Services, Inc.
• 16.25. Laboratory Corporation of America Holdings
• 16.26. Merck KGaA
• 16.27. Myriad Genetics, Inc.
• 16.28. Qiagen N.V.
• 16.29. Quanterix Corporation
• 16.30. Siemens Healthineers AG